Возраст домена | 12 лет |
Дата окончания | Истек срок регистрации |
ИКС | n/a |
Страниц в Google | 18 |
Страниц в Яндексе | n/a |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | Нет данных |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
See Our Proprietary Investment Strategy
life science investing, life science venture firm, venture firm success, proven track record, late-stage investing, clinical development, science investment
Valence Life Sciences is the only life sciences venture firm with a proven track record of success in late-stage investing. Our team has insight on what drives success from assessing management and clinical development plans for over 25 years.
UTF-8
32.85 КБ
340
2 809 симв.
2 384 симв.
Идет сбор информации... Обновить
Идет сбор информации... Обновить
Данные linkpad ( 5 Сентября 2017 ) | |
Количество ссылок на сайт | 3 |
Количество доменов, которые ссылаются на сайт | 2 |
Количество найденных анкоров | 2 |
Исходящие (внешние) ссылки домена | 105 |
Количество доменов, на которые ссылается сайт | 21 |
Количество исходящих анкоров | 16 |
Внешние ссылки главной страницы ( 16 ) | |
investors.leaptx.com/phoenix.zhtml?c=254460&p=irol-newsArtic... | Leap Therapeutics Offers $18 Million Private Placement Offering |
investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsPa... | Jazz Pharmaceuticals Announces FDA approval of VyxeosTM |
investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsAr... | Jazz Pharmaceuticals Announces Agreement to Acquire Celator Pharmaceuticals for $1.5 Billion |
investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsAr... | Jazz Pharmaceuticals Announces FDA Approval of Defitelio (Defibrotide) for Treatment of Hepatic Veno-Occlusive Disease |
ir.celatorpharma.com/releasedetail.cfm?ReleaseID=960543 | Celator Pharmaceuticals Announces Statistically Significant Improvement in Overall Survival in Phase III Trial for Vyxeos (CPX-3... |
ir.celatorpharma.com/releasedetail.cfm?ReleaseID=919224 | Celator Announces Positive Response Rate Results From Phase III Study of CPX-351 in High-risk AML Patients Demonstrating a 43% R... |
investors.invuity.com/phoenix.zhtml?c=253978&p=irol-newsArti... | Invuity Completes $55 Million IPO |
investor.anthera.com/releasedetail.cfm?ReleaseID=901728 | March 16, 2015 Anthera Announces Completion of Interim Analysis for Phase III trial with Blisibimod in IgA Nepropathy |
investor.anthera.com/releasedetail.cfm?ReleaseID=895609 | Anthera announces Completion of Interim Analysis for Phase III trial with Blisibimod in Lupus |
gentium.com/~/media/Files/G/Gentium-V2/pdf/press-releases/ge... | Gentium Announces Sale to Jazz Pharmaceuticals for $1 Billion |
ir.celatorpharma.com/releasedetail.cfm?ReleaseID=760704 | Celator Pharmaceuticals Raises $32.5 Million |
investors.invuity.com/phoenix.zhtml?c=253978&p=irol-newsArti... | Invuity Raises $25 Million in Series D Funding |
ir.vivus.com/releasedetail.cfm?ReleaseID=692685 | Vivus Announces FDA approval of Once Daily Qsymia for Obesity |
investors.arqule.com/releasedetail.cfm?ReleaseID=639538 | Arqule Announces Tivantinib Meets Primary Endpoint Extending TTP in Phase II trial in Hepatocellular Carcinoma |
201.sb.mywebsite-editor.com/app/cms/logout.php nofollow | Logout |
201.sb.mywebsite-editor.com/app/289401796/1150562104/ nofollow | Edit page |
Внутренние ссылки главной страницы ( 14 ) | |
valencefund.com/ | Home |
valencefund.com/team/ | Team |
valencefund.com/team/a-rachel-leheny-ph-d/ | A. Rachel Leheny, Ph.D. |
valencefund.com/team/eric-w-roberts/ | Eric W. Roberts |
valencefund.com/portfolio/ | Portfolio |
valencefund.com/industry-advisory-board/ | Industry Advisory Board |
valencefund.com/industry-advisory-board/dr-dani-p-bolognesi-... | Dr. Dani P. Bolognesi, Ph.D. |
valencefund.com/industry-advisory-board/robert-r-bonczek-j-d... | Robert R. Bonczek, J.D. |
valencefund.com/industry-advisory-board/peter-r-dolan/ | Peter R. Dolan |
valencefund.com/industry-advisory-board/dr-henry-a-mckinnell... | Dr. Henry A. McKinnell, Ph.D. |
valencefund.com/contact-us/ | Contact Us |
valencefund.com/s/cc_images/cache_3390813204.jpg?t=134512768... | <img> |
valencefund.com/legal-disclaimer/ | Legal Disclaimer |
valencefund.com/sitemap/ | Sitemap |
Domain Name: VALENCEFUND.COM
Registry Domain ID: 1689406722_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.register.com
Registrar URL: http://www.register.com
Updated Date: 2016-11-07T20:17:35Z
Creation Date: 2011-11-28T21:27:41Z
Registry Expiry Date: 2019-11-28T21:27:41Z
Registrar: Register.com, Inc.
Registrar IANA ID: 9
Registrar Abuse Contact Email: abuse@web.com
Registrar Abuse Contact Phone: +1.8003337680
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS-US.1AND1-DNS.COM
Name Server: NS-US.1AND1-DNS.DE
Name Server: NS-US.1AND1-DNS.ORG
Name Server: NS-US.1AND1-DNS.US
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-12-26T16:19:59Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
User-agent: *
Disallow: https://www.valencefund.com/c/
Disallow: https://www.valencefund.com/protected/
Disallow: /about-us/
Disallow: /team/jay-cecil/
Disallow: /team/scott-morenstein/
Disallow: /team/rob-ferraioli/
Disallow: /team/devon-e-coger/
Disallow: /news/
Disallow: /vls-pr-morenstein-and-ferraioli/
Disallow: /vls-press-release/
Disallow: /venturwire-article/
Disallow: /invuity-pr/
Disallow: /celator-pr/
Disallow: /industry-advisory-board/mr-leland-f-wilson/
Disallow: /2012-1/
Disallow: /2011-1/
Disallow: /2010-1/
Disallow: /2009-1/
Disallow: /2008-1/
Disallow: /2007-1/
Disallow: /2006-1/
Disallow: /legal-disclaimer/
Sitemap: https://www.valencefund.com/sitemap.xml
США - Филадельфия - 74.208.236.166
1&1 Internet AG
1&1 Internet
HTTP/1.1 200 OK
Content-Type: text/html; charset=UTF-8
Transfer-Encoding: chunked
Connection: keep-alive
Keep-Alive: timeout=15
Date: Fri, 18 Oct 2019 12:51:11 GMT
Server: Apache
Expires: Thu, 19 Nov 1981 08:52:00 GMT
Cache-Control: no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Pragma: no-cache
X-Content-Type-Options: nosniff
X-Xss-Protection: 0;report=https://cdn.initial-website.com/app/reporting/policyviolation/submit
Content-Security-Policy-Report-Only: default-src *;script-src 'unsafe-inline' 'unsafe-eval' *;style-src 'unsafe-inline' *;connect-src * blob:;report-uri https://cdn.initial-website.com/app/reporting/policyviolation/submit
Set-Cookie: DIY_SB=558e34e85be89100b7402bdf43f68004; path=/
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"